MEMais Emad

Mais Emad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mais Emad has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural Phenolic Compounds in Pain Management and Regenerative Medicine: From Molecular Mechanisms to Therapeutic Applications

    by Duaa Abuarqoub, Alqassem H. Abuarqoub, Mais Emad, Majd F. Ellauzi, Pascal A. Hattar

    Natural phenolic compounds are plant-derived compounds known for their potent antioxidant and anti-inflammatory properties. In addition, natural phenolic compounds are being investigated for their potential applications in pain management, and tissue engineering and regenerative medicine. This review aims to emphasize the anti-inflammatory and anti-oxidant effects of natural phenolic compounds and to highlight their important roles in pain management and tissue engineering and regenerative medicine. In pain management, natural phenolic compounds demonstrated promising results in suppressing orofacial, pelvic, neuropathic, and musculoskeletal pain compared to conventional pain management drugs or by synergistically acting with those drugs. While in tissue engineering and regenerative medicine, natural phenolic compounds were found to enhance the differentiation potential of stem cells into different lineages by increasing the expression of differentiation markers and were also found to enhance proliferation and migration of different types of dental stem cells. In conclusion, natural phenolic compounds, due to their unique properties, are promising in protocols of pain management as well as in tissue engineering and regenerative medicine.

  • Open Access

    Bioprinting the Craniofacial Region: A New Era in Regenerative Medicine and Dentistry

    by Duaa Abuarqoub, Mais Emad, Alqassem H. Abuarqoub, Majd F. Ellauzi, Tala Maragha

    Background: Three-dimensional (3D) printing and bioprinting have emerged as transformative technologies in tissue engineering and regenerative medicine. Conventional 3D printing enables the fabrication of complex, customizable scaffolds that mimic the native extracellular matrix (ECM), providing mechanical support essential for cell adhesion, proliferation, and differentiation. In contrast, 3D bioprinting integrates biomaterials, growth factors, and living cells into bioinks, allowing the precise layer-by-layer construction of tissue-like structures. Objective: This review aims to highlight recent advances and applications of both conventional 3D printing and 3D bioprinting in regenerative medicine, with a specific focus on craniofacial tissue regeneration. Particular emphasis is placed on the distinct roles of scaffold-based and cell-laden approaches. Methods: A comprehensive analysis of the current literature was conducted to examine both conventional 3D printing and bioprinting approaches used in craniofacial tissue engineering. Emphasis was placed on printing techniques, bioink composition and selection, scaffold design, and cell sources, as well as their applications across multiple tissue types. Results: Recent developments demonstrate that conventional 3D printing enables the fabrication of customizable scaffolds, whereas 3D bioprinting enables the generation of highly organized, cell-laden constructs that closely resemble native tissue architecture. These technologies have shown promising outcomes in developing patient-specific disease models and regenerative implants for craniofacial tissues, including bone, dental, tracheal, ocular, muscle, and neural tissues. Conclusions: 3D printing and bioprinting offer powerful platforms for craniofacial regenerative medicine. Ongoing advancements in bioink formulation, printing precision, and biological integration are expected to further enhance their translational and clinical potential.

  • Open Access

    Advancing Sports Injury Treatment Through Cell-Free MSC-Based Therapies: A Narrative Review

    by Duaa Abuarqoub, Alqassem H. Abuarqoub, Mais Emad, Majd F. Ellauzi

    Background: Sports-related musculoskeletal injuries, including tendon, ligament, muscle, and cartilage damage, often heal slowly and incompletely. Current treatments may not fully restore tissue function, necessitating regenerative therapies. Objective: This study was conducted to review the therapeutic potential of stem cell-derived extracellular vesicles (EVs) and conditioned medium (CM) as cell-free approaches to treating musculoskeletal injuries in sports medicine. Methods: A narrative review of preclinical and early clinical studies investigating the biological mechanisms and regenerative effects of mesenchymal stem/stromal cell (MSC)-derived EVs and CMs published between 2019 and 2026 was performed by searching Scopus, PubMed, Web of Science, and Google scholar. Results: EVs and CMs contain bioactive molecules, including microRNAs, cytokines, and growth factors, that modulate inflammation, promote tissue repair, enhance angiogenesis, and support extracellular matrix remodeling. Preclinical studies demonstrate improved healing of tendons, ligaments, muscles, and cartilage, while early clinical evidence suggests favorable safety and promising therapeutic outcomes. However, the variety of MSC sources, EV separation methods, characterization procedures, and treatment protocols present major challenges in determining the reliability and therapeutic efficacy of these therapies. Notably, the number of clinical studies on EV and CMs is still limited, and most of the available studies are in vitro studies. Conclusions: MSC-derived EVs and CMs represent promising cell-free regenerative therapies for sports-related musculoskeletal injuries. The available evidence, which demonstrates their ability to enhance healing while avoiding the challenges associated with cell-based therapies, highlights their translational potential. However, most of the studies that are now available are preclinical or early-stage clinical studies, and there is still a limited number of clinical trials. Further well-designed clinical studies are needed to establish standardized protocols and confirm long-term safety.